Site of progression after achievement of a response in those with primary HHV8-negative EBL
| Variable . | N = 18/64 . | No. of deaths . |
|---|---|---|
| Body cavity effusion | 12 (67%) | 8 |
| Effusion at the same site alone | 8 | 6 |
| Effusion at different sites | 2 | 0 |
| Presence of tumor mass (intracavitary or extracavitary) | 2 | 2 |
| Tumor mass without body cavity effusion | 6 (34%) | 2 |
| Variable . | N = 18/64 . | No. of deaths . |
|---|---|---|
| Body cavity effusion | 12 (67%) | 8 |
| Effusion at the same site alone | 8 | 6 |
| Effusion at different sites | 2 | 0 |
| Presence of tumor mass (intracavitary or extracavitary) | 2 | 2 |
| Tumor mass without body cavity effusion | 6 (34%) | 2 |